account_id none on file
legal_name none on file
ticker APGE
cik 1974640
domain apogeetherapeutics.com
linkedin_company_url https://www.linkedin.com/company/apogee-therapeutics/
entry_point_account_id none on file
name Apogee Therapeutics Inc.
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 0 family 0
why_nownone on file
callsnone on file
filings
Personnel-related expenses increased by $4.2 million in the three months ended June 30, 2026, compared to the three months ended June 30, 2025, primarily driven by increased headcount.
filing / Aug 10, 2026 / receipt
The increase of $6.9 million was primarily due to increases in personnel-related expenses of $2.0 million, driven by increased headcount and equity-based compensation of $1.7 million, primarily driven by the amortization of equity awards granted between the third quarter of 2025 and the second quarter of 2026.
filing / Aug 10, 2026 / receipt
In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures.
filing / Aug 10, 2026 / receipt
The increased costs may require us to reduce costs in other areas of our business or increase the prices of our product candidates, once commercialized.
filing / Aug 10, 2026 / receipt
Additionally, personnel-related expenses and equity-based compensation both increased by $3.2 million in the three months ended March 31, 2026, compared to the three months ended March 31, 2025, primarily due to increased headcount and an increase in the fair value of equity awards granted.
filing / May 11, 2026 / receipt
The increase of $5.3 million was primarily due to increases in equity-based compensation and personnel-related expenses of $2.9 million and $2.3 million, respectively, primarily driven by increased headcount and an increase in the fair value of equity awards granted.
filing / May 11, 2026 / receipt
In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures.
filing / May 11, 2026 / receipt
The increased costs may require us to reduce costs in other areas of our business or increase the prices of our product candidates, once commercialized.
filing / May 11, 2026 / receipt
executivesnone on file
familynone on file
upcomingnone on file
changesnone on file
mcp_package_hint
slug apogee-therapeutics-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$